Koenraad Debackere is a professor of Technology and Innovation Management & Policy at KU Leuven since 1995. He has degrees in engineering and business. He was a visiting doctoral student and Fulbright post-doctoral fellow at MIT Sloan School and obtained best paper awards from the TIM Division of the American Academy of Management, the Decision Sciences Institute and the International Association for the Management of Technology. In 2006 he was awarded the Prize for Scientific Excellence of the Belgian Entreprise Foundation (VBO). In 2007 he received an honorary professorship from the Science Policy Research Unit at the University of Sussex. He is the managing director of KU Leuven Research & Development and chairman of the KU Leuven seed fund, Gemma Frisius. He is co-founder and chairman of Leuven.Inc, the innovation network of Leuven high-tech entrepreneurs. Since 2005, he is the general manager of KU Leuven. In 2015, he was appointed chairman of EIT Health e.V. --- a KIC of the European Institute of Innovation and Technology.
Jo Bury is managing director of VIB, the Flanders Institute for Biotechnology. VIB is a life science research institute where 1.500 scientists and technicians study the molecular mechanisms of growth and development of different organisms (human beings, plants, micro-organisms) in normal (health) vs abnormal (disease, stress) conditions. The focus is strategic basic research with potential applications (in the long term) in molecular medicine and molecular farming. VIB is a multisite institution, integrated within the campuses of the universities of Ghent, Leuven, Brussels, Antwerp and Hasselt, based on a joint venture agreement of VIB with these 5 partner universities. Through the performance of its scientists, VIB has become a center of excellence in life science research in Europe.
Jo Bury has a Master’s degree in Pharmacy and is PhD in Pharmaceutical Sciences (University of Gent). He obtained an MBA degree at the Vlerick School for Management in Gent. After performing scientific research in the field of atherosclerosis during several years, he has made a career in science policy. He previously held the post of Operational Director of VLAB (Flanders’ Action Programme on Biotechnology) and science advisor at federal and regional granting bodies.